Logo
x

Search

Subscribe Now

Atopic Dermatitis

Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots

Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots

  • September 11, 2024
LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis

  • October 22, 2021
AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

  • October 8, 2021
Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2021

Sanofi Presents Results of Amlitelimab (KY1005) in P-IIa Study for the Treatment of Moderate-To-Severe Atopic Dermatitis at EADV 2...

  • October 1, 2021
Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

  • September 22, 2021
Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

  • September 10, 2021
Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

    Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

    • October 23, 2024
    Elanco Animal Health Reports the US FDA’s Approval of Zenrelia (Ilunocitinib) to Treat Canine Dermatological Disorders

      Elanco Animal Health Reports the US FDA’s Approval of Zenrelia (Ilunocitinib) to Treat Canine Dermatological Disorders

      • September 20, 2024
      Organon to Acquire Dermavant for an Aggregate of ~$1.2B

        Organon to Acquire Dermavant for an Aggregate of ~$1.2B

        • September 18, 2024
        Eli Lilly’s Ebglyss (L ebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis

          Eli Lilly’s Ebglyss (L ebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis

          • September 16, 2024
          Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots

            Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots

            • September 11, 2024
            Dechra Pharmaceuticals to Acquire Invetx, Expanding its Monoclonal Antibody Portfolio for Companion Animals

              Dechra Pharmaceuticals to Acquire Invetx, Expanding its Monoclonal Antibody Portfolio for Companion Animals

              • July 19, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.